Principles of the treatment of peritoneal carcinomatosis due to colorectal cancer. Current review and update;Bases y fundamentos del tratamiento de la carcinomatosis peritoneal por cáncer colorrectal. Revisión actual y puesta al día

Cirugia Espanola

Volumn 77, Issue 1, 2005, Pages 6-17

  Gómez Portilla, Alberto ^a   Cendoya, Iñaki ^a   de Tejada, Iñaki López ^a   Olabarria, Iñaki ^a   Magrach, Luis ^a   de Lecea, Concepción Martínez ^a   Gil, Alberto ^a   Valdovinos, Mercedes ^b   Larrabide, Iñaki ^b   de Alegría, Natalia Ruiz ^c   Fernández, José Luis ^c   Cachorro, Irune ^c   Contreras, María del Carmen ^c   Castañeda, Josu ^c   Uriarte, Arantxa ^c   Boado, María Victoria ^c   Urturi, José Antonio ^c   Ulibarrena, Miguelángel ^c  

^a Servicio de Cirugía   (Spain)

^b Policlínica San José   (Spain)

^c Servicio de Cuidados Intensivos   (Spain)

Author keywords

Colorectal carcinomatosis; Cytoreductive surgery; Intraperitoneal chemotherapy

Indexed keywords

CARCINOMA; CLINICAL TRIAL; COLORECTAL TUMOR; HUMAN; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PERITONEUM TUMOR; REVIEW;

CARCINOMA; CLINICAL TRIALS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; PERITONEAL NEOPLASMS;

EID: 33645457726     PISSN: 0009739X     EISSN: 1578147X     Source Type: Journal    
DOI: 10.1016/S0009-739X(05)70796-X     Document Type: Review

References (100)

1. Pestieau SR, Sugarbaker PH. Treatment of primary colon cancer with peritoneal carcinomatosis. comparasion of concomitant vs delayed management. Dis Colon Rectum. 2000;43:1341-8.
2. Bottomley A. Metastatic colorectal cancer: treatment challenges and quality of life. Lancet. 2002;359:1537-8.
3. Ortiz Hurtado H. Tratamiento quirúrgico y resultados del cáncer de colon. Presentación. Cir Esp. 2003;73:1.
4. Kindler HL, Shulman KL. Metastatic colorectal cancer. Curr Treat Options Oncol. 2001;2:459-71.
5. Dawson LE, Russell AH, Tong D, Wisbeck WM. Adenocarcinoma of the sigmoid colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. J Surg Oncol. 1983; 22:95-9.
6. De Bree E, Witkamp A, Zoetmulder FAN. Intraperitoneal chemotherapy for colorectal cancer [revisión]. J Surg Oncol. 2002;79:46-61.
7. Brodsky JT, Cohen AM. Peritoneal seeding following curative resection of colonic carcinoma: implicaton for adjuvant therapy. Dis Col Rectum. 1991;34:723-7.
8. Alonso O, Sugarbaker PH. Adult respiratory distress syndrome occurring in two patients undergoing cytoreductive surgery plus perioperative intraperitoneal chemotherapy. Case reports and a review of the literature. Am Surg. 2000;66:1032-6.
9. Sampson JA. Implantation peritoneal carcinomatosis of ovarian origin. Am J Pathol. 1931;7:423-43.
10. Chu DZJ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecological malignancy: a prospective study of prognostic factors. Cancer. 1989;63:364-7.
11. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivpoire M, Baulieux J, et al. Peritoneal carcinomatosis from nongynecological malignacies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358-63.
12. Esquivel J, Angulo F, Bland RK, Stephens AD, Sugarbaker PA. Hemodynamic and cardiac function parameters during heated intraoperative intraperitoneal chemotherapya using the open "coliseum technique". Ann Surg Oncol. 2000;7:296-300.
13. Scoggins CR, Meszoley IM, Blanke CD, Beauchamp RD, Leach SD. Nonoperative management of primary colorectal cancer in patients wit stage IV disease. Ann Surg Oncol. 1999;6:651-7.
14. Blair SL, Chu DZJ, Schwartz RE. Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from non-gynecological cancer. Ann Surg Oncol. 2001;8: 632-7.
15. Pilati P, Rossi CR, Mocellin S, Foletto M, Scagnet B, Pasetto L, et al. Multimodal tretament of peritoneal carcinomatosis and sarcomatosis. Eur J Surg Oncol. 2001;27:125-34.
16. Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol. 1999; 43(Suppl):S15-25.
17. Sugarbaker PH. It's what the surgeon doesn't see that kills the patient. J Nippon Med Sch. 2000;67:5-8.
18. Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545-50.
19. Witkamp AJ, De Bree E, Van Goethem AR, Zoetmulder FAN. Antitumour treatment. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev. 2001; 27:365-74.
20. Willet CG, Tepper JE, Cohen AM, Orlow E, Welch CE. Failure patterns following curative resection of colonic carcinoma. Surgery 1984;200:685-90.
21. Massacesi C, Pistilli B, Valeri M, Lippe P, Rocchi MBL, Cellerino R, et al. Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil based regimens. Am J Clin Oncol 2002;25:140-8.
22. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Metaanalysis Project [editorial]. J Clin Oncol. 1992;10:896-903.
23. Efficacy of intravenous continous infusion of 5-fluorouracil compared with bolus administration in advanced colorectal cancer: meta-analysis group in cancer [editorial]. J Clin Oncol. 1992;16: 301-8.
24. Levy-Piedbois C, Durand-Zaleski I, Juhel H, Schmitt C, Bellanger A, Piedbois P. Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. Ann Oncology. 2000;11:157-61.
25. Calvo E, Cortés J, González-Cao M, Rodríguez J, Aramendia JM, Fernández-Hidalgo O, et al. Combined irinotecan, oxaliplatin and 5-flourouracil in patients with advanced colorectal caner. A feasibility pilot study. Oncology. 2002;63:254-65.
26. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patinets with advanced or relapsed 5-flourouracil pretreated colorectal cancer [editorial]. Br J Cancer. 2001;85:1258-64.
27. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-47.
28. Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, et al. Phase II study of capecitabine and oxaliplatin in first and second line treatment of advanced or metastatic colorectal cancer. J Clin Oncol. 2002;7:1759-66.
29. Bliberg H, Hendlisz A. Advanced colorectal cancer treatment in Europe: what have we achieved? Review Paper. Anticancer Drugs. 2002;13:461-71.
30. Meropol NJ, Niedzwiecki D, Hollis D, Schilsky RL, Mayer RJ. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. Cancer. 2001;91:1256-63.
31. Van Custem E, Twelves CH, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer. Xeloda Colorectal Cance Study Group. Results of a large phase III study. J Clin Oncol. 2001;19:4097-106.
32. García Alonso P, Muñoz Martín AJ, García Adrián S. Tratamiento paliativo del cáncer colorrectal. Cir Esp. 2003;73:46-51.
33. De Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continous infusion for advanced colorectal cancer. A French Intergroup study. J Clin Oncol. 1997;15:808-15.
34. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparasion of continous infusion fluorouracil with conventional bolus schedule in metastatic colorectal carcinoma. A Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989;7:425-32.
35. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000; 343:905-14.
36. Douillard JY, Cunningham D, Roth AD, Navarro M, Karasek P, Jandik P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer. A multicenter randomised trial. Lancet. 2000;355:1041-7.
37. Tsavaris N, Kosmas CH, Vadiaka M, Koufos CH. Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecna/5-fluorouracil/leucovorin chemotherapy. BMC Cancer. 2002;2:2-15.
38. Grávalos Castro C, Pérez Escutia MA. Tratamiento adyuvante del cáncer colorrectal. Cir Esp. 2003;73:38-45.
39. Maughan TS, James RD, Kerr DJ, Ledermann JA, McArdle C, Seymour MT, et al. Comparasion of survival, pallation, and quality of life with three chemotherapy regimen in metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2002;359:1555-63.
40. Yonemura Y, Fujimura T, Fushida S, Takegawa S, Kamata T, Katayama K, et al. Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination.World J Surg. 1991;15:530-6.
41. Gertsch P. A historical perspective on colorectal liver metastases and peritoneal carcinomatosis: similar results, different treatments. Surg Oncol Clin North Am. 2003;12:531-41.
42. Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon's role. Langenbeck's Arch Surg. 1999;384:576-87.
43. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221: 29-42.
44. Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin North Am. 2003;12:703-27.
45. Yonemura Y. Principles of the treatment of peritoneal dissemination. En: Yonemura Y, editor. Peritoneal dissemination-molecular mechanisms and the latest therapy. Kanazawa, Japan: Maeda Shoten Co., Ltd.; 1998. p. 175-90.
46. Dubé P, Lasser Ph, Elias D. Traitement de la carcinose peritoneale d'origine colorectal. J Chir (Paris). 1997;134:233-6.
47. Elias DM, Pocard M. Treatment and prevention of peritoneal carcinomatosis from colorectal cancer. Surg Oncol Clin North Am: 2003; 12:543-59.
48. Gilly FN. Rationale for peritonectomy and periopertive intraperitoneal chemotherapy. Peritoneal surface malignancy. Third Biannual Masterclass in Peritoneal Surface maliganancy. Basingstoke: 2002.
49. Weissberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplatic origin. JAMA. 1955; 159:1704-7.
50. Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokineteic rationale drug administration in the treatment of ovarian cancer. Cancer Tret Rep. 1978;62:1-9.
51. Katz MH, Barone RM. The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface maloignacies. Surg Oncol Clin North Am. 2003;12:673-88.
52. Shen P, Levine EA, Hall J, Case D, Russell G, Fleming R, et al. Factors predicting survical after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arc Surg. 2003;138:26-33.
53. Sugarbaker PH, Gianola FJ, Speyer JC, Wesley R, Barofsky I, Meyers CE. Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery. 1985;98:414-21.
54. Gilly FN, Sayag AC, Carry PY, Brillon G, Roche M, James I, et al. Chimio-hyperthermie intra-peritoneale (CHIP) dans le traitament des carcninoses peritoneales d'origine digestive. Rapport d'une observation et données physiopathologiques. J Chir (Paris). 1990; 127:95-8.
55. Fujimoto S, Shrestha RD, Kokubun M, Ohta M, Takahashi M, Kobayashi K, et al. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg. 1988;208:36-41.
56. Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T. Prophylactic therapy for peritoneal recurrence of gastric cancer by continous hyperthermic peritoneal perfusion eith mitomycine C. Cancer. 1988;61:232-7.
57. Elias D, Dube P, Bonvalot S, Meshaka P, Manai M, Cavalcanti A, et al. Treatment of liver metestases with moderate peritoneal carcinomatosis by hepatectomy and cytoreductive surgery followed by inmediate postoperative intraperitoneal chemotherapy: feasibility and preliminary results. Hapatogastroenterol. 1999;46:360.
58. Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003;12:689-801.
59. Shido A, Ohmura S, Yamamoto K, Konayashi T, Fujimura T, Yonemura Y. Does hyperthermia induce peritoneal damage in continous hyperthermic peritoeal perfusion? World J Surg. 2000;24:507-11.
60. Spratt JS, Adcock RA, Sherill W, Travathen S. Hyperthermic peritoneal perfusion system in canines. Cancer Res. 1980;40:53-255.
61. Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40:2563-655.
62. Stuart OA, Stephens AD, Welch L, Sugarbaker PH. Safety monitoring of the coliseum tehnique for heated intraoperative intraperitoneal chemotherapy with mitomycin C. Ann Surg Oncol. 2002;9: 186-91.
63. Fujimoto S, Shrestha RD, Kokubun M, Kobayashi K, Kiuchi S, Ohta M, et al. Pharmacokinetic analysis of mitomycin C for intraperitoneal hyperthermic perfusion inpatients with far-advanced or recurrent gastric cancer. Reg Cancer Treat. 1989;2:198-202.
64. Panteix G, Guillaumont M, Cherpin L, Cuichard J, Gilly FN, Carry PY, et al. Study of the pharmacokinetics of mytomycin C in humans during intraperitoneal chemothermia with special mention of the concentration in local tissues. Oncology. 1993;50:366-70.
65. Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D, Sugarbaker PH. Heated intraoperatuve intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology. 1998;55:130-8.
66. Elias D, El Otmany A, Bonnay M, Pci A, Ducreux M, Antoun S, et al. Human Pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. Oncology. 2002;63:346-52.
67. Elias DM, Sideris L. Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin N Am. 2003;12:755-69.
68. Wientjes MG, Badalament RA, Wang RC, Hassan F, Au JL. Penetration of mitomycin C in human bladder. Cancer Res. 1993;53: 3314-20.
69. Glehen O, Gilly FN. Quantitative pognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am. 2003;12:649-71.
70. Gomez Portilla A, Sugarbaker PH, Chang D. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognosis features. World J Surg. 1999;23:23-9.
71. Gómez Portilla A, Sugarbaker PH. Segunda cirugía (second look) después de citorreducción y quimioterapia intraperitoneal en la carcinomatosis por cáncer colorrectal: análisis de factores pronósticos. Cir Esp. 1997;61:240-5.
72. Gómez Portilla A, Deraco M, Sugarbker PH. Clinical pathway for peritoneal carcinomatosis from colon and rectal cancer: guidelines for current practice. Tumori. 1997;83(Suppl):725-8.
73. Jacquet P, Stephens AD, Averbach AM, Chang D, Ettinghausen SE, Dalton RR, et al. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer. 1996;77:2622-9.
74. Stephens AD, Alderman R, Chang D, Edwards GD, Esquivel J, Sebbag G, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic heated intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999;6:790-6.
75. Esquivel J, Vidal-Jove J, Steves MA, Sugarbaker PH. Morbidity and mortatily of cytoreductive surgery and intraperitoneal chemotherapy. Surgery. 1993;113:631-6.
76. Elias D, Antoun S, Raynard B, Puizillout JM, Sabourin JC, Ducreux M, et al. Traitement des carcinoses peritonelaes par exérèse complète et chimiohyperthermie intraperitoneale. étude de phase I-II permettant de definir la meilleure procedure technique. Chirurgie. 1999;124:380-9.
77. Loggie BW, Fleming RA. Complications of heated intraperitoneal chemotherapy and strategies for prevention. Cancer Treat Res. 1996;82:221-33.
78. Yamaguchi A, Tsukoika Y, Fushida S, Kurosaka Y, Kanno M, Yonemura Y, et al. Intraperitoneal hyperthermic treatment for peritoneal dissemination of colorectal cancers. Dis Colon Rectum. 1992;35: 964-8.
79. Schneebaum S, Arnold MW, Staubus A, Young DC, Dumond D, Martin EW Jr. Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. Ann Surg Oncol. 1996;3:44-50.
80. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1996;6:727-31.
81. Elias D, Dubé P, Blot F, Bonvallot S, Eggenspieler P, Sabourin JC, et al. Peritoneal carcinomatosis treatment with curative intent: the Institute Gustave-Roussy experience. Eur J Surg Oncol. 1977;23: 317-21.
82. Elias D, Gachot B, Bonvallot S, Blot F, Sabourin JC, Ducreux M, et al. Carcinoses peritoneales traitées par exérèse complète et chimiotherapie intra-peritoneale postoperatoire immediate (CIPPI). étude de phase II portant sur 54 malades. Gastroenterol Clin Biol. 1997;21:181-7.
83. Fujimura T, Yonemura Y, Fujita H, Michiwa Y, Kawamura T, Nojima N, et al. Chemohyperthermic peritoneal perfusion for peritoneal dissemination in various intra-abdominal malignancies. Int Surg. 1999;84:60-6.
84. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surgeon. 2000;66:561-8.
85. Cavaliere F, Perri P, Di Filippo F, Giannarelli D, Botti C, Cosimelli M, et al. Treatment of peritoneal carcinomatosis with intent of cure. J Surg Oncol. 2000;74:41-4.
86. Beaujard AC, Glehen O, Caillot JL, Francois Y, Bienvenu J, Pantiex G, et al. Intraperitoneal Chemohyperthermia with mitomycin C for digestive tract caner patients with peritoneal carcinomatosis. Cancer. 2000;88:2512-9.
87. Rey Y, Porcheron J, Talabard JN, Szanfnicki K, Balique JG. Carcinoses peritoneales traitées par chirurgie de réduction tumorale et chimiohyperthermie intraperitoneale. Ann Chir. 2000;125:631-42.
88. Porcheron J, Talabard JN, Breton C, Szafnicki K, Luxembourger O, Dufraisse G, et al. Intraperitoneal chemohyperthermia for peritoneal carcinomatosis: original modeling, clinical tolerance and results study about 30 patients. Hepatogastroenterology. 2000;47:1411-8.
89. Piso P, Bektas H, Werner U, Schlitt HJ, Kubicka S, Bornscheuer A, et al. Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma. Eur J Surg Oncol. 2001; 27:286-90.
90. Elias D, Blot F, El Otmany A, Antoun S, Lasser P, Boige V, et al. Curative Treatment of Peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer. 2001;92:71-6.
91. Witkamp AJ, De Bree E, Kaag MM, Van Slooten GW, Van Coervorden F, Zoetmulder FAN. Extensive surgical cytoreduction and intra-operative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg. 2001;88:458-63.
92. Witkamp AJ, De Bree E, Kaag MM, Boot H, Beijnen JH, Van Slooten GW, et al. Extensive cytoreductive surgery followed by intraoperative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis from colorectal origin. Eur J Cancer. 2001;37:979-84.
93. Vaira M, Scuderi S, Castamagna D, Barone R, Aemo B, Mioli PR, et al. Cytoreductive surgery and intraperitoneal hyperthermic-antiblastic therapy (HAPP) in peritoneal carcinomatosis. Minerva Chir. 2002;57:579-605.
94. Shen P, Levine EA, Hall J, Case D, Russell G, Fleming RA, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg. 2003;138:26-33.
95. Sugarbaker Ph, Jablonski KA. Prognostic features of 51 colorectal and 130 appendicel cancer patinets with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221:124-32.
96. Sugarbaker PH, Schellinx MET, Chang D, Koslowe P, Von Meyerfeldt M. Peritoneal carcinomatosis from adenocacrinoma of the colon. World J Surg. 1996;20:585-92.
97. Zoetmulder FAN, Verwaal V. Hyperthermic intrapoeritoneal chemotherapy (HIPEC) with mitomycin C significantly improves survival in patients with peritoineal carcinomatosis of colorectal origin [resumen]. ASCO Prog Proc. 2002;21:a147.
98. Zoetmulder FAN. Prevention and treatment of carcinomatosis from colon cancer. Peritoneal surface malignancy. Third Biannual Masterclass in Peritoneal Surface maliganancy. Basingstoke, 2002.
99. Zoetmulder FAN. Hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis. XXXVIII Congress of the European Society for Surgical Research. Ghent, Belgium, mayo de 2003.
100. Verwaal VJ, Van Ruth S, De Bree E, Van Slooten GW, Van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21: 3737-43.